Two Sigma Investments LP Lowers Holdings in Compugen Ltd. (NASDAQ:CGEN)

Two Sigma Investments LP lowered its position in shares of Compugen Ltd. (NASDAQ:CGEN) by 27.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 54,042 shares of the biotechnology company’s stock after selling 20,141 shares during the quarter. Two Sigma Investments LP owned 0.06% of Compugen worth $83,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Northern Trust Corp boosted its stake in shares of Compugen by 936.9% in the fourth quarter. Northern Trust Corp now owns 941,825 shares of the biotechnology company’s stock valued at $1,441,000 after buying an additional 850,997 shares in the last quarter. Millennium Management LLC raised its position in Compugen by 77.5% in the fourth quarter. Millennium Management LLC now owns 359,397 shares of the biotechnology company’s stock worth $550,000 after acquiring an additional 156,959 shares in the last quarter. Silverarc Capital Management LLC grew its stake in shares of Compugen by 8.2% during the 4th quarter. Silverarc Capital Management LLC now owns 1,624,377 shares of the biotechnology company’s stock worth $2,485,000 after purchasing an additional 123,264 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Compugen in the 4th quarter valued at about $103,000. Finally, Jane Street Group LLC purchased a new position in shares of Compugen in the 4th quarter valued at about $81,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Stock Performance

Shares of CGEN stock opened at $1.64 on Friday. The stock has a fifty day moving average price of $1.45 and a 200 day moving average price of $1.69. The stock has a market cap of $146.35 million, a PE ratio of 82.00 and a beta of 2.54. Compugen Ltd. has a 1 year low of $1.13 and a 1 year high of $2.66.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Monday, May 19th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The firm had revenue of $2.28 million for the quarter, compared to analyst estimates of $3.70 million. During the same period last year, the firm earned ($0.08) EPS. As a group, equities research analysts predict that Compugen Ltd. will post -0.03 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.